NO OTHER ADDITIONAL FUNDING REQUESTS WILL BE CONSIDERED Sample Clauses

NO OTHER ADDITIONAL FUNDING REQUESTS WILL BE CONSIDERED. These amounts include all applicable taxes. All payments for this Study in accordance with the attached budget will be paid by CFS by wire transfer. • Příjem hodnoceného léčiva – podepsané a datované potvrzení o nepoškození a kompletnosti podle přiloženého dodacího listu (nebo není-li dosaženo tohoto požadavku); • Dodání hodnoceného léčiva na místo hodnocení a jeho označení; • Uskladnění hodnoceného léčiva, evidenci, příprava na destrukci nebo destrukce v případě potřeby (pak podle instrukcí Zadavatele/Quintiles); • Pravidelnou kontrolu Hodnoceného léčiva v místě hodnocení vybraným farmaceutem • Další povinnosti lékárny v souladu s protokolem a podpůrnou dokumentací po celou dobu průběhu klinického hodnocení. ADMINISTRATIVNÍ POPLATEK: CFS se zavazuje provést jednorázovou platbu do Zdravotnického zařízení za administrativní zpracování smlouvy ("administrativní poplatek") ve výši 10 000,-- Kč. Tato platba bude poskytnuta po uzavření smlouvy a po obdržení faktury ze Zdravotnického zařízení.
Sample 1Sample 2
AutoNDA by SimpleDocs
NO OTHER ADDITIONAL FUNDING REQUESTS WILL BE CONSIDERED. All amounts include all applicable taxes and excludes VAT. All payments for this Study in accordance with the attached Budget will be administered by IQVIA Clinical Trial Payments and paid by IQVIA electronically. ŽÁDNÉ DALŠÍ ŽÁDOSTI O FINANCOVÁNÍ NEBUDOU SCHVALOVÁNY. Všechny částky zahrnují veškeré příslušné daně, nikoli však DPH.
Sample 1
NO OTHER ADDITIONAL FUNDING REQUESTS WILL BE CONSIDERED. These amounts include all applicable taxes, except for VAT. All payments for this Study in accordance with the attached budget will be paid by DrugDev by wire transfer. Institution hereby agrees that all payments shall be made to the Payee exclusively by DrugDev budget table Payment Total in CZK Visit 3 Visit 5 Visit 6 Total 99,109 Procedures Total in CZK The compensation stated hereinabove also includes Investigator’s compensation and compensation for Study Staff. smlouva o klinickém hodnocení Tato smlouva o klinickém hodnocení (“Smlouva”) je uzavírána mezi následujícími stranami: Všeobecná fakultní nemocnice v Praze, se sídlem U Nemocnice 499/2, 128 08 Xxxxx 0, Xxxxx xxxxxxxxx, Identifikační xxxxx: 000 64 165, Daňové identifikační xxxxx: CZ00064165, zastoupená Mgr. Danou Juráskovou, Ph.D., MBA, ředitelkou (“Zdravotnické zařízení”), a XXXXXXXXXXXXXXXXXXXXXXXXX, narozen: XXXXXXXXXXXX, s adresou XXXXXXXXXXXX (“Zkoušející”), a Quintiles LTD, se sídlem 000 Xxxxx Xxxxx, Xxxxx Xxxx, Xxxxxxx, Xxxxxxxxx, XX0 0XX, Spojené království Xxxxx Xxxxxxxx a Xxxxxxxxx Xxxxx, XXX: GB450315485 (“Quintiles”), a Eisai Limited, se sídlem European Xxxxxxxxx Xxxxxx, Xxxxxxxx Xxx, Xxxxxxxx, Hertfordshire, AL10 9 SN Velká Británie, Identifikační xxxxx: 02242511, Daňové identifikační xxxxx: GB974835863, zastoupený XXXXXXXXXX (“Zadavatel”) Xxxxx samostatně jako “Strana” a společně jako “Strany”. Xxxxx Protokolu: E5501-G000-311 Název Protokolu: Randomizovaná, mezinárodní, dvojitě zaslepená, placebem kontrolovaná studie s paralelními skupinami k posouzení účinnosti a bezpečnosti avatrombopagu, podávaného perorálně jednou denně k léčbě dospělých s trombocytopenií v souvislosti s onemocněním jater před elektivním zákrokem Datum Protokolu: 12. listopadu 2013 Zadavatel: Eisai Limited Stát ve kterém má xxxxx Místo provádění klinického hodnocení, které provádí Studii Česká republika Místo, kde bude prováděna Studie: IV. Interní klinika 1. LF UK a XXX,X Xxxxxxxxx 0 Xxxxx 0 128 08, která je součástí/oddělením Všeobecné fakultní nemocnice v Praze. Klíčové datum zařazení: 100 kalendářních dnů po Iniciační návštěvě Místa provádění klinického hodnocení (a to jakožto den, ke kterému xx Xxxxx provádění klinického hodnocení povinno zařadit minimálně jeden (1) subjekt, jak xx xxxx podrobněji rozvedeno níže v odstavci 1.7 “Klíčové datum zařazení”) MEK / EK / SÚKL Etická komise FN Brno, Xxxxxxxxx 00, 000 00 Xxxx Xxxxx xxxxxxxxx Kontaktní osoba: XXXXXXXXXXXX Etická komise Všeobecné fakultní nemocnice v P...
Sample 1
NO OTHER ADDITIONAL FUNDING REQUESTS WILL BE CONSIDERED. All payments for this Study in accordance with the attached Budget will be paid by IQVIA by check and shall reference the Principal Investigator name, Sponsor name and Protocol.
Sample 1
NO OTHER ADDITIONAL FUNDING REQUESTS WILL BE CONSIDERED. These amounts include all applicable taxes with the exception of VAT. All payments for this Study in accordance with the attached budget will be paid by Quintiles by wire transfer.
Sample 1

Related to NO OTHER ADDITIONAL FUNDING REQUESTS WILL BE CONSIDERED

  • NO EXCEPTIONS OR REVISIONS WILL BE CONSIDERED In the event the Contract expires or is terminated for any reason, a Customer shall retain its rights under the Contract and the Purchase Order issued prior to the termination or expiration of the Contract. The Purchase Order survives the expiration or termination of the Contract for its then effective term.

  • EXCEPTIONS OR REVISIONS WILL BE CONSIDERED DIR shall have the absolute right to terminate the Contract without recourse in the event that:

  • All Terms to be Conditions The Company agrees that the conditions contained in this Agreement will be complied with insofar as the same relate to acts to be performed or caused to be performed by the Company. Any breach or failure to comply with any of the conditions set out in this Agreement shall entitle any of the Underwriters to terminate their obligation to purchase the Offered Shares, by written notice to that effect given to the Company at or prior to the Closing Time or the Option Closing Time, as applicable. It is understood that the Underwriters may waive, in whole or in part, or extend the time for compliance with, any of such terms and conditions without prejudice to the rights of the Underwriters in respect of any such terms and conditions or any other or subsequent breach or non-compliance, provided that to be binding on any Underwriter any such waiver or extension must be in writing and signed by such Underwriter.

  • Extent of Liability; Contribution (a) Notwithstanding anything herein to the contrary, each Borrower’s liability under this Section 5.11 shall be limited to the greater of (i) all amounts for which such Borrower is primarily liable, as described below, and (ii) such Borrower’s Allocable Amount.

  • No Rule of Strict Construction Regardless of which party may have drafted this Agreement, no rule of strict construction shall be applied against either party. If any provision of this Agreement is determined by a court to be unenforceable, the parties shall deem the provision to be modified to the extent necessary to allow it to be enforced to the extent permitted by law, or if it cannot be modified, the provision will be severed and deleted from this Agreement, and the remainder of this Agreement will continue in effect.

  • Representations and Warranties will be Relied Upon by the Company 8.1 The Subscriber acknowledges that the representations and warranties contained herein are made by it with the intention that such representations and warranties may be relied upon by the Company and its legal counsel in determining the Subscriber's eligibility to purchase the Shares under applicable securities legislation, or (if applicable) the eligibility of others on whose behalf it is contracting hereunder to purchase the Shares under applicable securities legislation. The Subscriber further agrees that by accepting delivery of the certificates representing the Shares on the Closing Date, it will be representing and warranting that the representations and warranties contained herein are true and correct as at the Closing Date with the same force and effect as if they had been made by the Subscriber on the Closing Date and that they will survive the purchase by the Subscriber of Shares and will continue in full force and effect notwithstanding any subsequent disposition by the Subscriber of such Shares.

  • Replacement of Lost Investments In the event of a loss of Investments for which the Custodian is responsible under the terms of this Agreement, the Custodian shall replace such Investment, or in the event that such replacement cannot be effected, the Custodian shall pay to the Fund the fair market value of such Investment based on the last available price as of the close of business in the relevant market on the date that a claim was first made to the Custodian with respect to such loss, or, if less, such other amount as shall be agreed by the parties as the date for settlement.

  • Several Obligations; Benefits of this Agreement The respective obligations of the Lenders hereunder are several and not joint and no Lender shall be the partner or agent of any other (except to the extent to which the Agent is authorized to act as such). The failure of any Lender to perform any of its obligations hereunder shall not relieve any other Lender from any of its obligations hereunder. This Agreement shall not be construed so as to confer any right or benefit upon any Person other than the parties to this Agreement and their respective successors and assigns, provided, however, that the parties hereto expressly agree that the Arranger shall enjoy the benefits of the provisions of Sections 9.6, 9.10 and 10.11 to the extent specifically set forth therein and shall have the right to enforce such provisions on its own behalf and in its own name to the same extent as if it were a party to this Agreement.

  • No Additional Waiver Implied by One Waiver In the event any agreement contained in this Site Lease should be breached by either party and thereafter waived by the other party, such waiver shall be limited to the particular breach so waived and shall not be deemed to waive future compliance with any term hereof or any other breach hereunder.

  • Not Responsible for Recitals or Issuance of Notes The recitals contained herein and in the Notes, except the Trustee’s certificates of authentication, shall be taken as the statements of the Company, and the Trustee or any Authenticating Agent assumes no responsibility for their correctness. The Trustee makes no representations as to the validity or sufficiency of this Indenture or of the Notes. The Trustee or any Authenticating Agent shall not be accountable for the use or application by the Company of Notes or the proceeds thereof.

Time is Money Join Law Insider Premium to draft better contracts faster.